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Introduction: Percutaneous computed tomography (CT)-guided 
lung biopsy is a standard minimally invasive technique for sampling 
peripheral lung lesions. Radial endobronchial ultrasound (EBUS) 
offers an alternative approach but it has yet to be defined which 
patients are most suited to this procedure. The primary aim of this 
study was to investigate whether CT characteristics could predict the 
success of radial EBUS-guided sampling.
Methods: The University Hospital South Manchester provides a 
radial EBUS service, under conscious sedation without fluoroscopy, 
double-hinged curettes, or guide sheaths, to a large cancer Network 
in the United Kingdom. This retrospective analysis of a prospectively 
maintained database included all patients undergoing radial EBUS 
from January 2011 to June 2013. Lesion size, structure, location, and 
presence of a bronchus sign on thoracic CT were analyzed against 
predefined outcomes using multivariate analysis.
Results: One-hundred and seventeen patients underwent radial 
EBUS in the study period (mean age 69.5, mean lesion size 36.6 mm). 
The presence of a bronchus sign on CT was the only independent 
predictor of all predefined outcomes: (1) lesion identification with 
radial EBUS, (2) positioning of probe within the center of the 
lesion, and (3) accurate pathological diagnosis; odds ratio (OR) 31.1 
(7.8–123.9, p < 0.0001), OR 44.8 (5.6–354.9, p < 0.0001) and OR 
46.6 (11.1–195.3, p < 0.0001) respectively. The sensitivity and diag-
nostic accuracy for those patients with a bronchus sign on CT was 
87.3% and 86.7% compared with 12.5% and 11.1% for those lacking 
the bronchus sign.
Discussion: The patients most likely to benefit from radial EBUS, 
without the use of adjuncts, are those with a bronchus sign on CT.
Key Words: Endobronchial ultrasound, Bronchoscopy, Computed 
tomography, Lung cancer, EBUS, EBUS-TBB, Radial probe
(J Thorac Oncol. 2014;9: 1393–1397)
Radial endobronchial ultrasound (EBUS), performed during flexible bronchoscopy, has gained increasing acceptance 
as a feasible method of locating and facilitating sampling of 
peripheral lung lesions. The associated literature supported 
the publication of an Interventional Procedure Guidance by 
the National Institute for Clinical Excellence in 2010 (N2124) 
and a meta-analysis of 1420 patients from 16 studies in 2011.1 
The favorable safety profile of radial EBUS-guided sampling 
is a consistently reported advantage over percutaneous com-
puted tomography (CT)-guided biopsy where the risk of pneu-
mothorax is up to 25%.2–4 The complication rate from radial 
EBUS is considerably lower including a risk of pneumothorax 
of approximately 1%.1,5–10 In contrast, meta-analysis report a 
higher pooled sensitivity for percutaneous CT-guided biopsy 
compared with radial EBUS; 90% versus 73%, respectively.1,11
Patient selection and the place of radial EBUS in the 
diagnostic pathway have not been clearly defined. The tech-
niques and environment used by expert groups around the 
world, from which many publications have emanated, may not 
be transferable to general respiratory practice. For example, 
many studies investigating radial EBUS have used fluoroscopy 
and a double-hinged curette to help guide the radial probe. 
Others have used guide sheaths to guide sampling instruments 
after the probe has been removed.5–7,10 General anesthesia is 
also frequently undertaken in the same studies. These adjuncts 
to radial EBUS add cost and complexity to the procedure and 
may be limiting factors for general bronchoscopists. If radial 
EBUS is to become accessible to all patients as part of rou-
tine diagnostics, it is unlikely these adjuncts will be widely 
adopted.
Certain factors are consistently shown to be associated 
with improving the diagnostic accuracy of the radial EBUS. 
First, identification of the target lesion with radial EBUS 
improves diagnostic accuracy.1 Second, locating the radial 
probe at the center of the lesion (as opposed to adjacent to the 
lesion) improves accuracy (Fig. 1).5,7,10 However, both these 
factors are “intra-operative” findings and cannot be used to 
select appropriate patients before the procedure. The aim of 
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this study was to prospectively evaluate which factors, based 
on pre-procedure CT imaging, were associated with: (1) lesion 
identification, (2) location of the probe within the center of the 
lesion and (3) increased diagnostic accuracy in a population of 
patients undergoing radial EBUS without any adjuncts (fluo-
roscopy, curettes, guide sheaths or general anesthesia).
MATERIALS AND METHODS
The University Hospital of South Manchester provides 
the only radial EBUS service within Manchester Cancer, a 
large cancer Network in the United Kingdom that includes a 
regional cancer center. Respiratory physicians, thoracic sur-
geons, medical and clinical oncologists can all refer patients 
for radial EBUS. The accepted indication for radial EBUS is 
a target pulmonary lesion, located distal to the central airways 
unlikely to be visible with standard diagnostic bronchoscopy. 
There are two referral pathways through which patients may 
undergo radial EBUS at our center. First, patients are referred 
specifically for radial EBUS to sample a target lesion. This 
pathway will include patients with: (1) a solitary peripheral 
pulmonary lesion requiring pathological diagnosis, most often 
a suspected primary lung cancer, (2) suspected advanced lung 
cancer requiring histological diagnosis alone and the periph-
eral pulmonary disease is deemed the most appropriate site 
to sample, and (3) suspected peripheral pulmonary metas-
tases from a non-primary lung cancer. All such referrals are 
accepted, without selection criteria. Second, a patient referred 
for linear EBUS nodal staging of suspected lung cancer may 
also, in addition, undergo radial EBUS if it is felt appropri-
ate to sample the primary tumor by the primary operator. 
Factors that are considered when deciding to proceed with 
radial EBUS include: the likelihood of achieving a patho-
logical diagnosis from nodal sampling and the tolerability of 
bronchoscopy (linear EBUS nodal staging is considered the 
priority of the procedure if tolerance is poor). A team of four 
operators perform all procedures; two lung cancer physicians, 
a nurse consultant bronchoscopist, and a lung cancer fellow. 
Each operator has extensive experience in diagnostic flexible 
bronchoscopy ranging between 5 and 21 years. We have been 
performing linear and radial EBUS since 2010 with prospec-
tively collected data on key performance indicators.
Bronchoscopy is performed under conscious sedation 
with incremental doses of midazolam and alfentanyl, without 
anesthetic support. Endobronchial disease is excluded using 
a standard diagnostic bronchoscope (Olympus BFF260 or 
BF6C260) before the selective cannulation of the target 
lobe (and subsegmental airways) using a 1.7 mm 20 MHz 
radial ultrasound probe. If the target lesion is identified, the 
distance from the lesion to the tip of the bronchoscope is 
measured using the same method previously described by 
Fuso et al.9 The radial probe is removed and biopsy forceps 
introduced into the same subsegmental bronchi and biopsies 
taken at the appropriate distance from the bronchoscope. 
Fluoroscopy, guide sheaths, and double-hinged curettes are 
not used. Rapid on-site evaluation of specimens is unavail-
able. A minimum of five biopsies per lesion are taken assum-
ing safety, patient comfort and tolerance. A post procedure 
chest x-ray is only performed if: (1) a patient reports any 
symptoms suggestive of a pneumothorax including breath-
lessness, chest pain, or shoulder pain or (2) a patient reports 
pain when a biopsy is taken, as recommended in the British 
Thoracic Society Guidelines 2013.12
Detailed patient-related and procedural data are pro-
spectively recorded for all patients undergoing EBUS pro-
cedures at University Hospital of South Manchester onto 
a central database. For those patients undergoing radial 
EBUS, the following characteristics are recorded before 
commencing bronchoscopy: size of lesion (mm, in largest 
axis on CT), lobar location on CT (right upper lobe, right 
middle lobe, right lower lobe, left upper lobe, or left lower 
lobe), the presence or absence of a bronchus sign (defined 
as a bronchus leading directly into the lesion on CT), and 
structure (solid, mixed, or ground glass). After the proce-
dure the bronchoscopist records the following information: 
if the target lesion was identified with radial EBUS, if the 
probe was located in the center of or adjacent to lesion 
(Fig. 1) and complications (categorized as major or minor as 
described in UK national guidelines).12 Radial EBUS sam-
ples are examined by a specialist thoracic pathologist and 
classified according to standard pathological criteria using 
both structure and immunohistochemistry. The pathological 
results from radial EBUS-guided sampling, the results of 
any subsequent sampling of the target lesion (undertaken at 
the discretion of the referring doctor) and the outcome of 
6 months of clinical-radiological follow-up are added to the 
database when available.
FIGURE 1. A, Radial endobronchial 
ultrasound (EBUS) image with the 
radial probe positioned within the 
center of the target lesion, the lesion 
is present 360 degrees around the 
probe. (B) Radial EBUS image with 
the radial probe positioned adjacent 
to the target lesion, the probe is only 
partially in contact with the lesion.
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This study is a retrospective analysis of the prospec-
tively maintained database. All patients that underwent radial 
EBUS from January 2011 to June 2013 were included. The 
outcome of radial EBUS-guided sampling was classified 
as “positive” (defined as confirming malignancy), “true- 
negative” (defined as no malignancy demonstrated from radial 
EBUS and no evidence of malignancy on any subsequent 
sampling and 6 months of clinical-radiological follow-up) or 
“false-negative” (defined as no malignancy from radial EBUS 
but malignancy confirmed on further sampling or assumed by 
clinical-radiological follow-up). If radial EBUS diagnosed a 
nonmalignant pathology, e.g., tuberculosis, this was classified 
as negative and further classified as “true-negative” if there 
was no evidence of malignancy on any subsequent sampling 
and 6 months follow-up. For data analysis, three binary out-
come categories were produced: (1) lesion identified with 
radial EBUS versus no lesion identified, (2) probe in the cen-
ter of the lesion versus probe not in the center (adjacent or not 
identified), and (3) accurate diagnosis (defined as “positive or 
true-negative” sampling) versus inaccurate diagnosis (defined 
as the lesion not identified or “false-negative” sampling). 
Individual factors (size <20 mm versus >20 mm, size <30 mm 
vs >30 mm, location of the lesion, the presence or absence of a 
bronchus sign, and structure solid versus non-solid) were ana-
lyzed against each of the three binary outcome measures using 
both univariate (χ2 tests) and multivariate analysis (multiple 
logistic regression). Two different size categories were chosen 
(30 mm is the cutoff used to define a pulmonary nodule and 
mass, and 20 mm was identified as a relevant size in a recent 
meta-analysis).1 Factors significant at the 10% level in uni-
variate analysis were included in the multivariate analysis. If 
both size categories were found to be significant in univariate 
analysis the categorization with the most significant p value 
was used in multivariate analysis. Odds ratios with a 95% 
confidence interval are presented for the multivariate analysis. 
Standard definitions were used to calculate overall sensitiv-
ity and negative predictive value for radial EBUS, with the 
denominator for the former defined as the number of patients 
with malignancy and not according to the binary outcomes 
described above.
RESULTS
One-hundred and seventeen patients underwent radial 
EBUS examination in the study period. The mean age was 
69.5 and 53% were male. Many patients were of good perfor-
mance status (64%, PS0-1). The overall prevalence of malig-
nancy was high at 83% (Table 1). The mean size of the target 
lesion was 36.6 mm. Many lesions were in the upper lobes 
(62%, 72 of 117) and were of solid structure (88.9%, 104 of 
117, Table 2).
Overall, radial EBUS identified an abnormality consis-
tent with the target lesion leading to subsequent biopsy in 82% 
of patients (96 of 117). In the remaining 18% (21 of 117), the 
target lesion was not identified and no biopsy was performed. 
In the 96 patients in whom the target lesion was identified, the 
radial probe was located in the center of the lesion in 68% (65 
of 96) and adjacent to the lesion in 32% (31 of 96). Overall, the 
bronchus sign was present in 77% (90 of 117) and absent in 
23% (27 of 117) patients. Ninety-six patients underwent radial 
EBUS-guided biopsies and 68% (65 of 96) were malignant. Of 
the 31 negative biopsies, 48% (15 of 31) were subsequently 
proven to be false negatives. The verification of negative radial 
EBUS biopsies was pathological in 45% (14 of 31; surgical 
biopsy n = 9, CT-guided biopsy n = 4, EBUS-TBNA of nodal 
TABLE 1.  Patients Characteristics
Mean age (±SD) 69.5 (+/−9.9)
Sex: M/F (%M) 62/55 (53)
Performance status
n (%)
0 23 (19.7)
1 52 (44.4)
2 30 (25.6)
3 11 (9.4)
4 1 (0.9)
Lung function
mean (±SD)
FEV1, liters 1.7 (±0.6)
FEV1, % predicted 77.4 (±31.4)
DLCO, % predicted 60.2 (±23.0)
Indication for radial 
endobronchial 
ultrasound 
n (%)
Isolated lung lesion 63 (53.8)
Adjunct to nodal staging 34 (29.1)
Advanced lung cancer 17 (14.5)
Pulmonary metastases 3 (2.6)
Final diagnosis
n (%)
NSCLC; adenocarcinoma 39 (33.3)
NSCLC; squamous cell carcinoma 27 (23.1)
NSCLC; NOS 7 (6.0)
NSCLC; large cell 2 (1.7%)
Small cell lung cancer 5 (4.3%)
Non-primary lung cancer 6 (5.1%)
Clinical diagnosis of lung cancer, 
without pathological confirmation
11 (9.4)
Benign pathology* 20 (17.1%)
*Benign pathology; lesions resolved on surveillance imaging presumed 
inflammatory n = 8, cryptogenic organizing pneumonia n = 4, tuberculosis n = 3, 
postsurgical inflammatory tissue n = 2, chronic inflammation on surgical resection n = 1, 
sarcoidosis n = 1, fungal infection n = 1.
FEV1,forced expiratory volume in 1 second; DLCO, carbon monoxide diffusing 
capacity; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified.
TABLE 2.  Pulmonary Lesion Characteristics
Size Mean (±SD) 36.6 (±13.4)
Size
n (%)
<20 mm 15 (12.8)
>20 mm 102 (87.2)
<30 mm 36 (30.8)
>30 mm 81 (69.2)
Lesion location
n (%)
Right upper lobe 40 (34.2)
Left upper lobe 32 (27.3)
Right middle lobe 12 (10.3)
Right lower lobe 19 (16.2)
Left lower lobe 14 (12.0)
Bronchus sign
n (%)
Absent 27 (23.1)
Present 90 (76.9)
Lesion structure
n (%)
Solid 104 (88.9)
Mixed 10 (8.5)
Ground glass 3 (2.6)
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disease n = 1), and clinical-radiological in 55% (17 of 31). 
The overall performance of radial EBUS, when procedures 
where the target lesion was not identified are classified as false 
negatives, was as follows: sensitivity 64.4%, negative predic-
tive value 44.4%, and diagnostic accuracy (defined as the % 
overall correct diagnosis) was 69.2%. When these calculations 
are restricted to only those patients in whom the target lesion 
was identified and a biopsy was performed, the performance 
was as follows: sensitivity 81.3%, negative predictive value 
51.6%, and diagnostic accuracy 84.4%. Malignant or true 
negative biopsies were obtained in 97% (63 of 65) of biopsies 
when the radial probe was positioned within the center of the 
lesion compared with 35% (18 of 52) in the remaining patients, 
including those in whom the target lesion was unidentified.
The lobar location of the lesion and lesion structure had 
no effect on lesion identification, probe position, or accurate 
diagnosis (Tables 3–5). On univariate analysis, a lesion size 
>20 mm and >30 mm was associated with a significantly higher 
rate of lesion identification, central probe placement, and accu-
rate diagnosis. However, on multivariate analysis, only a lesion 
size of >30 mm was an independent variable associated with a 
higher rate of central probe placement (p = 0.016). In contrast 
to these results, the presence of a bronchus sign was a highly 
significant independent predictor of lesion identification, cen-
tral probe placement, and accurate on multivariate analysis 
(p < 0.0001 for all three outcomes, Tables 3–5). The sensitivity 
and diagnostic accuracy, using the number of patients with or 
without malignancy as the denominator, were 87.3% and 86.7% 
for those patients with a bronchus sign on CT, compared with 
12.5% and 11.1% for those lacking the bronchus sign.
There was one major complication from radial EBUS; a 
pneumothorax requiring intercostal chest tube (0.9%). There 
were nine minor complications (7.7%); six bleeding requiring 
treatment with cold saline or adrenaline, two poor tolerance of 
bronchoscopy requiring premature termination of the proce-
dure and one episode of intra-operative hypotension requiring 
intravenous fluids. Epidermal growth factor receptor mutation 
analysis was required on malignant tissue provided by radial 
EBUS-guided biopsies in 20 patients. Adequate tissue for 
meaningful testing was provided in 100% of cases and 10% 
(two of 20) demonstrated a targetable activating mutation.
DISCUSSION
If diagnostic accuracy is comparable, radial EBUS with-
out adjuncts should have several advantages over radial EBUS 
TABLE 3.   Univariate and Multivariate Analysis of Factors 
Associated with Lesion Identification Using radial EBUS
Factor
Lesions 
Identified Univariate Multivariate
Size <20 mm 9/15 (60%) p <0.0001
>20 mm 89/102 (87%)
Size <30 mm 22/36 (61%) p = 0.001
>30 mm 73/81 (90%)
Location Right upper lobe 32/40 (80%) p = 0.42 —
Left upper lobe 25/32 (78%)
Right middle lobe 10/12 (83%)
Right lower lobe 14/19 (74%)
Left lower lobe 14/14 (100%)
Bronchus
 Sign
Absent 9/27 (33%) p < 0.0001 Odds ratio 31.1 
(7.8–123.9)
Present 86/90 (96%) p < 0.0001
Structure Non-solid 12/13 (92%) p = 0.30 —
Solid 83/104 (80%)
TABLE 4.  Univariate and Multivariate Analysis of Factors 
Associated with the Radial Probe Being Positioned Within the 
Center of the Target Lesion
Factor
Probe in the 
Center of the 
Lesion Univariate Multivariate
Size <20 mm 1/15 (7%) p = 0.003
>20 mm 63/102 (62%)
Size <30 mm 9/36 (25%) p < 0.0001 Odds ratio 
1.3–10.2
>30 mm 55/81 (68%) p = 0.016
Location Right upper lobe 20/40 (50%) p = 0.41 —
Left upper lobe 15/32 (47%)
Right middle lobe 8/12 (67%)
Right lower lobe 10/19 (53%)
Left lower lobe 11/14 (79%)
Bronchus  
sign
Absent 1/27 (4%) p < 0.0001 Odds ratio 44.8 
(5.6–354.9)
Present 64/90 (71%) p < 0.0001
Structure Non-solid 6/13 (46%) p = 0.47 —
Solid 83/104 (80%)
TABLE 5.  Univariate and Multivariate Analysis of Factors 
Associated with a Successful Radial EBUS-Guided Biopsy 
(Successful Defined as a Malignant Biopsy or True-Negative 
Biopsy)
Factor
Successful 
Biopsy Univariate Multivariate
Size <20 mm 4/15 (27%) p = 0.001
>20 mm 77/102 (75%)
Size <30 mm 17/36 (47%) p = 0.001
>30 mm 64/81 (79%)
Location Right upper 
lobe
28/40 (70) p = 0.983 —
Left upper  
lobe
20/32 (63%)
Right middle 
lobe
10/12 (83%)
Right lower 
lobe
11/19 (58%)
Left lower  
lobe
12/14 (86%)
Bronchus sign Absent 3/27 (11%) p < 0.0001 Odds ratio 
46.6 
(11.1–195.3)
Present 78/90 (87%) p < 0.0001
Structure Non-solid 10/13 (77%) p = 0.53 —
Solid 71/104 (68%)
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with adjuncts; requiring less time, less cost, and better patient 
tolerability. Reduced procedure time is particularly important 
in those patients undergoing EBUS-TBNA nodal staging in 
the same procedure (30% in this cohort). The sensitivity of 
radial EBUS in this study was 64% which is lower than the 
pooled sensitivity for all radial EBUS of 73%,1 but compa-
rable with the only previous study of radial EBUS without 
adjuncts by Fuso et al. (59%).9
The main aim of this study was to establish how patients 
might be selected for radial EBUS based on CT imaging. The 
presence of a bronchus sign was the most important factor; it 
was an independent predictor of lesion identification, central 
probe placement and accurate diagnosis regardless of lesion 
size, location, or structure. We accept a certain degree of co-lin-
earity between lesion size and the presence of a bronchus sign. 
For example, 84% (86 of 102) of lesions >20 mm were accom-
panied by a positive bronchus sign compared with 27% (four 
of 15) of lesions <20 mm. However, the multivariate analysis 
clearly demonstrates that the bronchus sign is a far stronger pre-
dictor of the predefined outcomes than size. The sensitivity of 
radial EBUS in patients with a bronchus sign is comparable with 
that of percutaneous CT-guided biopsy (86.7% versus 90%).11 
These results are in contrast to previous studies of radial EBUS 
and the bronchus sign. Yamada et al.10 performed a retrospective 
review of 158 lesions and demonstrated that only identification 
of the lesion with radial EBUS was an independent predictor 
of biopsy success on multivariate analysis. However, only 58 
patients were eligible for CT assessment of the bronchus sign. 
Furthermore, a number of adjuncts were used which may lessen 
the importance of the bronchus sign. Hsia et al. also performed 
a retrospective review of 40 patients undergoing radial EBUS 
also using several adjuncts. No effect of the bronchus sign was 
found on multivariate analysis but the small sample size may be 
a limiting factor. In contrast to these two studies of radial EBUS 
with adjuncts, the bronchus sign has been shown to increase 
diagnostic yield in both transbronchial lung biopsy under fluo-
roscopy13,14 and electromagnetic navigational bronchoscopy.15
We acknowledge a degree of selection bias in our series as 
the decision to refer for radial EBUS is at the discretion of other 
physicians around the Network where the factors used to select 
patients are unknown to us. In particular, our cohort is likely 
to contain patients deemed unsuitable for percutaneous biopsy, 
e.g., because of emphysema and a high risk of pneumothorax.
In summary, radial EBUS without fluoroscopy or other 
adjuncts is a safe and effective method of sampling periph-
eral lung lesions. This retrospective analysis of prospectively 
collated data suggests that the patients most likely to bene-
fit from radial EBUS are those with a bronchus sign on CT. 
Such patients can expect a high degree of diagnostic accu-
racy regardless of lobar location and structure. Size may be 
a contributing factor to the success of radial EBUS but the 
bronchus sign appears to be a superior predictive tool for this 
patient cohort. A randomized controlled trial with the bron-
chus sign as a requirement for inclusion and endpoints that 
include diagnostic accuracy, complication rate, cost effective-
ness, and patient satisfaction would seem justifiable.
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